Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amaryl M IR
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Amaryl M IR is a fixed-dose combination medication containing glimepiride and metformin hydrochloride in an immediate release formulation. It is used for the management of type 2 diabetes mellitus when diet, exercise, and single agent therapy (glimepiride or metformin alone) do not result in adequate glycemic control. Glimepiride works by stimulating the pancreas to release more insulin, while metformin helps reduce blood sugar production by the liver and improves insulin sensitivity.
- Brand names
- Amaryl M IR
- Other names
- Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet
02
Targets
SUR2A (ATP-binding cassette sub-family C member 9)SUR1 (Sulfonylurea receptor 1)
Beyond the preview
Go deeper on Amaryl M IR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amaryl M IR.